-

USANA Health Sciences to Participate in the 25th Annual ICR Conference

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA), a leading developer and manufacturer of high-quality nutritional supplements, healthy foods and personal care products, today announced that Doug Hekking, Chief Financial Officer, will present and host one-on-one meetings with investors at the ICR Conference in Orlando, FL on January 9-10, 2023. The presentation will begin at 3:30PM ET on January 10, 2023.

A live audio webcast of the presentation will be available on USANA’s website at https://ir.usana.com and a replay will be available on the same day.

About USANA

USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Italy, Romania, Spain, and Germany. More information on USANA can be found at www.usana.com.

Contacts

Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7210
investor.relations@usanainc.com

Media contact:
Dan Macuga
Public Relations
(801) 954-7280

USANA Health Sciences, Inc.

NYSE:USNA

Release Versions

Contacts

Investor contact:
Andrew Masuda
Investor Relations
(801) 954-7210
investor.relations@usanainc.com

Media contact:
Dan Macuga
Public Relations
(801) 954-7280

More News From USANA Health Sciences, Inc.

USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026. Key Financial and Operating Results   Q4 2025   Q4 2024   FY 2025   FY 2024 Net sales $226.2   $213.6   $925.3   $854.5 Net (loss) earnings* $-1.8   $4.5   $10.8   $42.0 Diluted EPS $-0.10   $0.23   $0.58   $2.19 Adjusted diluted EPS(1) $0.60   $0.64   $1.93   $2.59 Adjusted EBITDA(2) $27.3   $25.5   $101.3   $110.3 USAN...

USANA Health Sciences Provides Preliminary Fiscal Year 2025 Net Sales and Issues Initial Fiscal Year 2026 Net Sales Outlook

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA’s strategy, including the Company’s initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 cons...

Kevin Guest Returns to USANA Health Sciences as CEO

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) announced today a leadership transition as part of the Company’s ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA’s CEO and wi...
Back to Newsroom